Curious to see your top suppliers emissions?
Book a demo for a pilot project
Cspc Pharmaceutical
Pharmaceutical Preparation ManufacturingHong Kong SAR ChinaHKSE: 1093.HK
Last verified 5 months agocspc.com.hk
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in developing a diverse range of high-quality pharmaceutical products, including innovative prescription medications and over-the-counter solutions.
Cspc operates extensively across major regions, including Asia and Europe, and is recognised for its commitment to research and development, which has led to numerous breakthroughs in therapeutic areas such as oncology and cardiovascular health. With a strong market position, Cspc has garnered accolades for its advanced manufacturing capabilities and adherence to stringent quality standards, solidifying its reputation as a trusted name in the global pharmaceutical landscape.
31
DitchCarbon score
-9 vs industry average
Cspc Pharmaceutical’s score of 31 is lower than 45% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cspc Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
20202021202220232024202520262027
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Cspc Pharmaceutical's reported carbon emissions
CSPC Pharmaceutical, a company in the Pharmaceutical Preparation Manufacturing industry based in Hong Kong, has reported Scope 1 and Scope 2 emissions for several years.
For the reporting year 2024, CSPC Pharmaceutical reported approximately 474,567,040 kg CO2e for Scope 1 emissions and approximately 493,310,000 kg CO2e for Scope 2 emissions.
In 2023, the company's Scope 1 emissions were around 663,224,000 kg CO2e and Scope 2 emissions were approximately 418,037,000 kg CO2e.
For 2022, Scope 1 emissions were about 564,429,000 kg CO2e, and Scope 2 emissions were approximately 572,613,000 kg CO2e.
In 2021, Scope 1 emissions amounted to approximately 580,318,000 kg CO2e, with Scope 2 emissions at about 600,682,000 kg CO2e.
The company's Scope 1 emissions in 2020 were approximately 348,756,000 kg CO2e, and Scope 2 emissions were around 698,828,000 kg CO2e.
For 2019, Scope 1 emissions were approximately 231,562,000 kg CO2e, and Scope 2 emissions were about 892,873,000 kg CO2e.
In 2018, the company reported total emissions of approximately 981,708,420 kg CO2e, with Scope 1 and Scope 2 data not separately specified for that year.
For 2017, Scope 1 emissions were approximately 1,108,844,970 kg CO2e, Scope 2 emissions were about 53,566,610 kg CO2e, and Scope 3 emissions were approximately 44,547,340 kg CO2e. The total emissions for 2017 were approximately 1,206,958,920 kg CO2e.
CSPC Pharmaceutical has established several greenhouse gas emission reduction targets related to intensity per unit of revenue. These include a near-term target to reduce greenhouse gas emissions per unit revenue by 53% by 2026, and another near-term target to reduce emissions per unit revenue by 60% by 2030. Additionally, there are targets to reduce greenhouse gas emissions per unit revenue by 56% for the periods of 2027-2028 for both Scope 1 and Scope 2 emissions. The company also committed in 2021 to reference the suggestions of the Task Force on Climate-related Financial Disclosures (TCFD) to minimise its carbon footprint from operational activities.
The data is not cascaded from a parent organization.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cspc Pharmaceutical’s Climate Goals (2030 & 2050)
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
On track94%
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
At risk48%
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Behind target22%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Cspc Pharmaceutical5 months ago
31
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more